- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04124510
Efficacy and Safety of Flutiform K-haler in Patients With Uncontrolled Asthma Following Mid-dose ICS/LABA DPI Therapy (SWIFT)
An 12-week, Prospective, Interventional, Single-arm, Multi-centre, Phase III Study to Examine the Efficacy and Safety of Flutiform K-haler in Asthma Patients Who Are Not Adequately Controlled by Mid-doseICS/LABA DPI Treatment
Study Overview
Detailed Description
Asthma is a chronic inflammatory allergic disease of airway involving many cells and various media. Airway inflammation causes various symptoms of airway hypersensitivity, including repeated wheezing, dyspnea, and tightness in the chest. An estimated 300 million people worldwide suffer from asthma, and in South Korea, an estimated asthma prevalence rate for adults is approximately 5% [1]. For more effective management of asthma, Global Initiative for Asthma (GINA) guideline[2] and Korean Asthma Management Guideline for Adults [1] suggests that for patients who cannot have asthma symptoms under control with ICS (Inhaled Corticosteroid) alone, concomitant treatment of ICS/LABA is more effective than dose increase of ICS, and therefore recommends ICS combined with Long-acting β2-agonist (LABA) products. Common ICS/LABA products that are available in the Korea market including dry power inhaler (DPI) and pressured metered dose inhaler (pMDI).
It is known that small airway significantly contributes to total airway resistance, so the inflammation of the small airways could lead to the poor asthma control observed since small airways are not directly reached by inhaler's particles [3,4]. Fluticasone/formoterol (Flutiform®) shows a high fine particle fraction (FPF) of about 40% for both the ICS and the LABA components regardless the inhalation flow rate[5]. FPF of Fluticasone/formoterol is significantly higher than other ICS/LABA combinations. It is expected that small particles of fluticason/formoterol could reach to the large/small airways easier than other ICS/LABA combinations even if these ICS/LABAs shows a similar efficacy for asthma treatment. However Asthma patients can struggle to use their pMDI inhalers correctly due to the need to properly co-ordinate the press and inhale, which can worsen their asthma and lead to exacerbations.
Flutiform K-haler is the first breath-actuated inhaled corticosteroid (ICS) long-acting β2-agonist (LABA) combination aerosol inhaler for adults and adolescents. The flutiform k-haler has been designed with patients in mind, requiring only a gentle inhalation to trigger the dose release, with the aim to help patients reduce critical errors and improve long-term outcomes.
Therefore, It is expected that Flutiform K-haler prevents exacerbation and improves symptom of Asthma. Especially it will be beneficial to patients who did not response to existing ICS/LABA DPI in Korea. This study is planned to examine the efficacy and safety of Flutiform K-haler in patients who are not adequately controlled by previous mid-dose ICS/LABA DPI treatment.
Study Type
Enrollment (Actual)
Phase
- Phase 3
Contacts and Locations
Study Locations
-
-
-
Seoul, Korea, Republic of, 05030
- Konkuk University Medical Center
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Korean asthma patients age ≥ 19 years old
- Patients who have moderate to severe persistent asthma, as defined by GINA 2018 guideline, with ICS/LABA DPI use history
- Patients who have uncontrolled asthma in FEV1 up to 60% and Asthma control test score < 20
- Female subjects of child bearing potential must have a negative urine pregnancy test prior to first dose of study medication and that they must be agree to use adequate contraception during the study period
- Patients who are able to use the inhaler
- Patients who is willing to voluntarily sign the study consent form
Exclusion Criteria:
- Patients who have diagnosed as clinically significant pulmonary diseases
- Patients who have experienced life-threatening asthma within 12 months prior to screening or respiratory infection within 4 weeks prior to screening, or patients who have experienced any emergency visit or hospitalization due to acute asthma symptoms within 4 weeks prior to screening
Current and past smoker: Smoker defined as below
- Current smoker: smoking history within 90 days prior to screening
- Past smoker: smoking amount >10 pack year
- Patients who currently are pregnant or lactating
- Patients who are participating or going to participate in any interventional clinical trials
- QT interval prolongation in ECG result at screening (420msec > male, 440msec > female)
- Patients with hypersensitive to investigational products or to any component of the drug
- Patients requiring treatment with any of the prohibited concomitant medications Use of the following medications is prohibited during the study due to drug-to-drug interaction with the study drug
- Patients who took SPIRIVA within 3 month prior to enrollment
- Patients who did not show previous DPI drug compliance between 70% ~130%
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Brand Name: Flutiform K-haler
Brand Name: Flutiform K-haler Generic name: Fluticasone/formoterol dosage form: oral inhalation
|
Brand Name: Flutiform K-haler Generic name: Fluticasone/formoterol dosage form: oral inhalation
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
The primary endpoint of the study is the change in Asthma control test from baseline to Week 12 on treatment
Time Frame: Week 0, Week 12
|
change in Asthma control test from baseline to Week 12 on treatment
|
Week 0, Week 12
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Kwang Ha Yoo, Konkuk University Medical Center
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- FLT18-KR-301
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Asthma
-
Vanderbilt University Medical CenterNot yet recruitingAsthma in Children | Asthma Attack | Asthma Acute | Acute Asthma Exacerbation | Asthma; StatusUnited States
-
University of California, San FranciscoCompletedAsthma in Children | Asthma Attack | Asthma Acute | Asthma ChronicUnited States
-
Johann Wolfgang Goethe University HospitalCompleted
-
Universita di VeronaCompleted
-
Parc de Salut MarActive, not recruitingAsthma in Children | Persistent Asthma | Asthma ExacerbationSpain
-
Forest LaboratoriesCompleted
-
Brunel UniversityKarolinska InstitutetUnknown
-
Value Outcomes Ltd.AstraZenecaCompletedAsthma, Bronchial | Bronchial Asthma | Asthma Chronic | Asthma; EosinophilicCzechia
-
Johann Wolfgang Goethe University HospitalCompletedExercise-induced AsthmaGermany
Clinical Trials on Brand Name: Flutiform K-haler
-
Medical University InnsbruckCompleted
-
Weill Medical College of Cornell UniversityUniversity of Catania; University of Stirling; Hunter College of The City University...CompletedSchizophrenia and Related DisordersUnited States
-
The Hospital for Sick ChildrenCompletedCystic FibrosisCanada
-
Asan Medical CenterDaewoong Pharmaceutical Co. LTD.RecruitingHeart Failure With Preserved Ejection Fraction | Tricuspid RegurgitationKorea, Republic of
-
Leo WangBTS InternationalCompletedWeight | Body Fat Disorder | Bone MassChina
-
Cairo UniversityCompletedImmediate Dental ImplantsEgypt
-
Seoul National University HospitalCompleted
-
Sheffield Teaching Hospitals NHS Foundation TrustCompleted
-
CONKO-StudiengruppeFresenius AGCompletedPancreatic Cancer | Cancer CachexiaGermany
-
Kirby InstituteJanssen-Cilag Ltd.CompletedHepatitis C, ChronicAustralia